Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis

被引:10
作者
Chow, Ronald [1 ]
Yin, Leyi Bellinda [1 ]
Baqri, Wafa [1 ]
Huang, Ryan [1 ]
Boldt, Gabriel [2 ]
Younus, Jawaid [2 ]
Lock, Michael [2 ]
Prsic, Elizabeth [3 ]
Zimmermann, Camilla [1 ]
Herrstedt, Jorn [4 ]
机构
[1] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
[2] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada
[3] Yale Univ, Yale Sch Med, New Haven, CT USA
[4] Univ Copenhagen, Copenhagen, Denmark
关键词
Chemotherapy-induced nausea and vomiting; Delayed phase; Long-delayed phase; HIGHLY EMETOGENIC CHEMOTHERAPY; CINV STUDY-GROUP; DOUBLE-BLIND; POSTCHEMOTHERAPY NAUSEA; ANTIEMETIC EFFICACY; PLUS DEXAMETHASONE; INTRAVENOUS DEXAMETHASONE; CANCER-CHEMOTHERAPY; TROPISETRON NAVOBAN; INDUCED EMESIS;
D O I
10.1007/s00520-023-07978-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionAlthough there have been reports of chemotherapy-induced nausea and vomiting (CINV) beyond 120 h, its overall prevalence has not been systematically examined. The aim of this review and meta-analysis was to report on the prevalence of this long-delayed CINV.MethodsThis review was registered on PROSPERO (CRD42022346963). PubMed (Medline), Embase, and Cochrane Central were searched from inception until August 2022. Articles were included if they reported on CINV > 120 h after initiation of the chemotherapy regimen and patients received a single-agent highly emetogenic (HEC) or moderately emetogenic (MEC) antineoplastic agent for 1 day alone or in combination with low/minimal emetogenic chemotherapy. For all eligible articles, individual study authors were contacted and requested to provide individual patient-level data of demographics, emetogenicity of chemotherapy regimens, and daily incidence of nausea and vomiting. Forward stepwise logistic regression identified predictors for the incident day's CINV based on prior day's CINV episodes, controlling for patient demographics, and stratified by regimen emetogenicity.ResultsA total of 2048 patients from 2 studies were included in this individual patient data meta-analysis: 1333 patients (65%) received HEC and 715 (35%) received MEC. Among those receiving HEC, 325 (24%) experienced acute, 652 (49%) delayed, and 393 (31%) long-delayed nausea; 107 (8%) experienced acute, 179 (14%) delayed, and 79 (6%) long-delayed vomiting. Among those receiving MEC, 48 (7%) experienced acute, 272 (38%) delayed, and 167 (24%) long-delayed nausea; 12 (2%) experienced acute, 97 (14%) delayed, and 42 (6%) long-delayed vomiting. Nausea in the long-delayed phase was as severe as in the delayed phase. Patients experiencing nausea and vomiting on days 4 and 5 were at significant risk of experiencing long-delayed CINV.ConclusionWhile not as prevalent as delayed nausea and vomiting, long-delayed CINV affects a significant proportion of patients and severity is similar. Patients with delayed CINV, specifically on days 4-5, are at risk of experiencing long-delayed CINV.
引用
收藏
页数:11
相关论文
共 85 条
  • [1] A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
    Aapro, MS
    Thuerlimann, B
    Sessa, C
    de Pree, C
    Bernhard, J
    Maibach, R
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (02) : 291 - 297
  • [2] Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
    Ando, Yosuke
    Hayashi, Takahiro
    Ito, Kaori
    Suzuki, Eri
    Mine, Naoyuki
    Miyamoto, Ayumi
    Oya, Miyuki
    Matsuda, Hidezo
    Isaji, Ami
    Nakanishi, Toru
    Imaizumi, Kazuyoshi
    Shibata, Tomoyuki
    Okada, Tatsuyoshi
    Sakurai, Kazuo
    Naito, Kensei
    Uyama, Ichiro
    Kawada, Kenji
    Takahashi, Hiroshi
    Yamada, Shigeki
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 871 - 878
  • [3] Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan
    Baba, Yoshifumi
    Baba, Hideo
    Yamamoto, Sachiko
    Shimada, Hideaki
    Shibata, Tomotaka
    Miyazaki, Tatsuya
    Yoshikawa, Takaki
    Nakajima, Yasuaki
    Tsuji, Yasushi
    Shimokawa, Mototsugu
    Kitagawa, Yuko
    Aiba, Keisuke
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (02)
  • [4] Babu Govind, 2016, Chemother Res Pract, V2016, P3439707, DOI 10.1155/2016/3439707
  • [5] Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance)
    Barton, Debra L.
    Thanarajasingam, Gita
    Sloan, Jeff A.
    Diekmann, Brent
    Fuloria, Jyotsna
    Kottschade, Lisa A.
    Lyss, Alan P.
    Jaslowski, Anthony J.
    Mazurczak, Miroslaw A.
    Blair, Scott C.
    Terstriep, Shelby
    Loprinzi, Charles L.
    [J]. CANCER, 2014, 120 (22) : 3575 - 3583
  • [6] Treatment of nausea and emesis during cancer chemotherapy:: Discrepancies between antiemetic effect and well-being
    Börjeson, S
    Hursti, TJ
    Tishelman, C
    Peterson, C
    Steineck, G
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 24 (03) : 345 - 358
  • [7] A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin
    Bossi, P.
    Cortinovis, D.
    Fatigoni, S.
    Rocca, M. Cossu
    Fabi, A.
    Seminara, P.
    Ripamonti, C.
    Alfieri, S.
    Granata, R.
    Bergamini, C.
    Agustoni, F.
    Bidoli, P.
    Nole, F.
    Pessi, M. A.
    Macchi, F.
    Michellini, L.
    Montanaro, F.
    Roila, F.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2547 - 2551
  • [8] Chow KS., 1999, CAN J HOSP PHARM, V52, P371
  • [9] Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis
    Chow, Ronald
    Navari, Rudolph M.
    Terry, Bryan
    DeAngelis, Carlo
    Prsic, Elizabeth Horn
    [J]. SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1015 - 1018
  • [10] Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
    Chow, Ronald
    Herrstedt, Jorn
    Aapro, Matti
    Chiu, Leonard
    Lam, Henry
    Prsic, Elizabeth
    Lock, Michael
    DeAngelis, Carlo
    Navari, Rudolph M.
    [J]. SUPPORTIVE CARE IN CANCER, 2021, 29 (07) : 3439 - 3459